## IQV: IQVIA Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.95 indicates fundamental undervaluation. Quality metrics strong (ROE 19%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($206.40)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term**
- Source: www.sharewise.com | 20251209T160817 | Bullish | Relevance: 99%
-  IQVIA Holdings (IQV) is identified as a top momentum stock due to its strong performance in Zacks Style Scores, specifically an A for Momentum and an overall VGM Score of A. The article highlights IQV's consistent earnings estimate revisions and its status as a #3 (Hold) on the Zacks Rank, making it an attractive option for investors focused on upward trends. IQVIA, a prominent player in the life sciences industry, is currently seeing upward revisions in its fiscal 2025 earnings estimates from analysts.

**2. North Growth Management Ltd. Invests $5.22 Million in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251208T122519 | Bullish | Relevance: 99%
-  North Growth Management Ltd. recently purchased a new stake of 33,000 shares in IQVIA Holdings Inc. (NYSE:IQV), valued at approximately $5.22 million. This move is part of broader institutional investor activity, with several other firms increasing their holdings in the medical research company. The article also notes recent insider stock sales and provides an overview of analyst ratings and IQVIA's financial performance.

**3. IQVIA Holdings amends credit agreement to refinance loans and reduce interest rates**
- Source: Investing.com | 20251209T221116 | Somewhat-Bullish | Relevance: 99%
- IQVIA Holdings Inc. announced amendments to its Fifth Amended and Restated Credit Agreement, refinancing existing term loans into new classes and consolidating revolving credit commitments. The restructuring also reduces the interest rate for U.S. dollar-denominated term A loans and revolving credit loans by removing the term SOFR credit spread adjustment. Furthermore, the Swiss and Japanese subsidiary borrowers are released from their obligations under the credit agreement.

**4. IQVIA Holdings Inc. $IQV Shares Sold by Quantbot Technologies LP**
- Source: MarketBeat | 20251209T120812 | Somewhat-Bullish | Relevance: 98%
-  Quantbot Technologies LP significantly reduced its stake in IQVIA Holdings Inc. ($IQV) by 54.3% in the second quarter, selling 8,552 shares and retaining 7,206 shares valued at approximately $1.14 million. Despite this, institutional investors collectively own about 89.62% of the company's stock, with several other firms increasing their positions. IQVIA recently exceeded Q2 earnings and revenue expectations, reporting $3.00 EPS and $4.10 billion in revenue, and analysts maintain a "Moderate Buy" rating with a target price of $241.44.

**5. Amundi Acquires 405,250 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251207T230832 | Bullish | Relevance: 98%
-  Amundi has increased its stake in IQVIA Holdings Inc. by 46.3%, acquiring an additional 405,250 shares, bringing its total holdings to 1,279,817 shares valued at $210.7 million. Despite institutional investor Eric Sherbet selling 4,000 shares, institutional ownership of IQVIA remains high at 89.62%. The company recently reported earnings that slightly beat expectations and provided optimistic FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |
| 2025-11-13 | BMO Capital | $260 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-13 | BMO Capital | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 1 ($5.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.4% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.8M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.1B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.8% to -4.6% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.21x) but short-term weakness (below SMA20). MACD histogram bearish (-1.25), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.57% (CS: 21) | Weak |
| RSI_14 | 45.8 | Neutral |
| MACD Histogram | -1.25 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.014x | Above |
| vs SMA200 | 1.206x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $218.06
- **Stop Loss:** $206.40 (5.3% risk)
- **Target:** $241.38 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $5,451.50
- **Portfolio %:** 5.45%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*